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Cell sizeThe mechanisms of programmed cell death activate genetically encoded intracellular programs in a controlled
manner, themost common formbeing apoptosis. Apoptosis is carried out through a cascade of caspasemediated
proteolytic cleavages initiated by the oligomerization of Bax, a cardinal regulator of mitochondrial-mediated
apoptosis. Heterologous expression of Bax in yeast causes cell death that shares a number of similarities to pro-
cesses that occur in mammalian apoptosis. A screen of a cardiac cDNA library for suppressors of Bax-mediated
apoptosis identiﬁed human septin7, a protein that belongs to the septin superfamily of conserved GTP-binding
proteins that share a conserved cdc/septin domain. Analysis of the amino acid sequence deduced from the
septin7 clone as well as the corresponding human septin7 gene revealed that a novel alternatively spliced tran-
script called septin7 variant4 (v4) was uncovered. Yeast cells overexpressing the human septin7 v4 cDNA were
also capable of resisting copper-mediated cell death suggesting that it is not only a Bax suppressor but also an
anti-apoptotic sequence. Analysis of septin7 function in a MCA1Δ yeast strain suggests that septin7 inhibits
apoptosis in a caspase independent pathway. Overexpression of the yeast septin7 ortholog CDC10 also conferred
resistance to the negative effects of copper as well as protecting cells from the overexpression of Bax. In contrast,
septin7 was unable to prevent the increase in cell size associated with mutants lacking the endogenous yeast
CDC10 gene. Taken together, our analysis suggests that anti-apoptosis is a novel yet evolutionarily conserved
property of the septin7 sub-family of septins.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Activation of programmed cell death (PCD) can occur in response to
a multitude of stresses that are extracellular (heavy metals, pesticides,
hydrogen peroxide, etc.) or internal (DNA damage, endoplasmic reticu-
lum stress, misfolded proteins, etc.) [1–4]. These stresses lead to the
activation of a variety of different pro-apoptotic proteins which in
turn serve to induce cell death via a multitude of pathways [2,5]. At its
simplest, the basic framework of PCD can be broken down into three
distinct but interrelated or cross-talking pathways that include apopto-
sis, necrosis and autophagy [6,7]. A simpliﬁed version of apoptotic cell
death involves the stress mediated activation of pro-apoptotic Bax
and subsequent or simultaneous increase in pro-apoptotic second
messengers such as Reactive Oxygen Species (ROS) [2,8]. This leads
to sequential and/or simultaneous activation of pro-apoptotic Bcl-2
proteins (i.e. Bax) and mitochondrial damage/permeabilization [2,7].nd Chemical Engineering, Royal
gston, Ontario K7K 7B4, Canada.
enwood).
ights reserved.Mitochondrially derived apoptogenic factors including cytochrome c
(Cyt c), Apoptosis Inducing Factor (AIF) and endonuclease G (EndoG)
are released. Cyt c is involved in the formation of an executioner caspase
(i.e. caspase3) activating complex (apoptosome) that serves to cleave
key proteins leading to cell death, while free EndoG enters the nucleus
and participates in death inducing processes by cleaving DNA. More
recently stress mediated activation of RIP kinases appears to be a key
component of regulated forms of necrosis such as necroptosis [9]. In ad-
dition to the activation of key pro-death proteins there is an increase in
the levels of a number of pro-death second messengers, including the
previously mentioned and well-known ROS, as well as a variety of
others including ceramide, iron and calcium [2]. These pro-apoptotic
second messengers are known to be increased in response to stresses
and serve as intermediaries in the process of activating PCD pathways.
The regulation of apoptosis requires a plethora of anti-apoptotic or
pro-survival genes. These serve to prevent pre-mature or unwanted
PCD [10–12]. The importance of negative regulation can be illustrated
in a number of convincing ways including the fact that the decreased
expression or the knock-out of many pro-survival genes leads to in-
creased sensitivity to the lethal effects of stresses [2]. Conversely the
increased expression of many pro-survival genes leads to signiﬁcant
stress resistance [13]. Clinically, the increased stress resistance observed
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sion of pro-survival genes [8]. In effect the analysis of the transcriptome
of tumor cells has been instrumental in the identiﬁcation of many anti-
apoptotic genes [14]. For example, the most potent anti-apoptotic gene,
Bcl-2, was originally found as a pro-survival gene up-regulated in tumor
cells [15]. The mechanism by whichmany anti-apoptotic proteins func-
tion to prevent PCD is rather straightforward in that they serve to coun-
teract well established pro-apoptotic processes [2,7]. For example, Bcl-2
appears to function by counteracting Bax, genes encoding enzymes such
as super oxide dismutase function by scavenging stress mediated
increases of ROS, while sphingomyelin synthase 1 (SMS1) functions
by decreasing the levels of the pro-apoptotic sphingolipid ceramide by
utilizing it as a substrate to make sphingomyelin [13]. Identiﬁcation of
novel anti-apoptotic sequences is an ongoing process that not only
serves to reinforce existing concepts but to also aid in uncovering new
processes involved in the regulation of PCD [16]. For example, the iden-
tiﬁcation of the DUT gene encoding the dUTP hydrolyzing enzyme
dUTPase as an anti-apoptotic gene suggests that dUTP is a pro-
apoptotic stress induced second messenger [17,18]. The identiﬁcation
of the DUT as a gene that is present in the genome of some viruses
and that it is up-regulated in certain tumors suggests that dUTP may
have specialized functions as a pro-apoptotic secondmessenger [17,19].
Over the last dozen or so years, the yeast Saccharomyces cerevisiae
has emerged as a model system that shares many of the same features
of mammalian stress induced PCD [3,5]. A number of recent studies
highlight the unique perspective of studying PCD in the genetically
amenable yeast. For example, analysis of aging mediated PCD in yeast
suggests that the polyamine spermidine and the red wine anti-aging
compound resveratrol function to prolong lifespan by inducing autoph-
agy [20]. This process appears to be of general importance since it was
also observed in other organisms including nematodes and ﬂies. Yeast
has also proven to be useful for the identiﬁcation and the characteriza-
tion of mammalian gene encoding apoptotic regulators. Thus the heter-
ologous expression of mammalian genes in yeast, so-called humanized
yeast systems, has also proven to generate novel insights [21–23]. For
example, the overexpression of the Parkinson's associated α-synuclein
in yeast recapitulates many of the aspects of the processes of PCD in
this disease [24]. Recent insight has been gained by the identiﬁcation
of the Golgi-resident plasmamembrane-related Ca2+/ATPase 1 as a po-
tential mediator of α-synuclein mediated alterations in Ca2+ levels and
cytotoxicity [25].
We previously reported the identiﬁcation of a number of novel pro-
survival sequences by screening mammalian cDNA expression libraries
in yeasts undergoing Baxmediated cell death [16,26]. Herewe report on
the characterization of a novel Bax suppressor identiﬁed as human
septin7. Our analysis suggests that septin7 is a not a Bax suppressor
but instead it has the characteristics of a general anti-apoptotic gene.
In addition, overexpression of one of the yeast septin encoding genes,
CDC10, also confers resistance to the lethal effects of copper and Bax.
Taken together our results indicate that the septin7 sub-family of
septins represents a novel and conserved class of anti-apoptotic
sequences.
2. Materials and methods
2.1. Yeast strains, plasmids and growth
The S. cerevisiae BY4742 (MATα his3Δ1 leu2Δ0 lys15Δ0 ura3Δ0)
strain was used as the wild type strain. The mutant strains lacking the
MCA1 or CDC10 gene are isogenic to BY4742 (Thermo Scientiﬁc). Plas-
mids containing the cDNAs for septin7 (Bh17) and 14-3-3 expressed
under the control of the galactose inducible GAL1 promoter in pYES-
DEST52 were isolated in our previously described Bax screen [13,26].
The plasmid for the galactose inducible expression of the yeast CDC10
on aURA3 yeast selectablemarker was obtained from Thermo Scientiﬁc.
Mouse Bax under the regulation of the yeast GAL1 promoter was on aplasmid with a HIS3 selectable marker as previously described [26].
Plasmids were introduced into yeast using the lithium acetate method
and selected for and maintained by the omission of the appropriate nu-
trient. Yeast cells were routinely grown in synthetic minimal media
containing yeast nitrogen base (YNB), 2% glucose with the required
amino acids and base. Glucose was replaced with 2% rafﬁnose and 2%
galactose to induce the expression of the sequences under the control
of the GAL1 promoter.
2.2. Spot and viability assays
Yeast transformants maintained on YNB glucose agar plates were
used to inoculate liquid YNB glucose media and grown for 16–24 h by
shaking at 30 °C. The freshly saturated overnight cultures were used
to inoculate liquid YNBmedia containing rafﬁnose and galactose and in-
cubated for 4–6 h with shaking at 30 °C. Aliquots of the cultures were
then sequentially serially diluted (1:5) with sterile distilled water and
5 μl of each dilution was spotted onto nutrient agar media and subse-
quently incubated at 30 °C for three or four days. Spot assays were
repeated for a minimum of three times. Sterile copper sulfate (CuSO4)
was added to the plates at the concentrations indicated in the ﬁgures.
Rapamycin spot assays were performed as previously described [13].
For viability assays, 1.4 mM of CuSO4 was added to the fresh cultures
growing in galactose and then grown for a further 18 h with shaking
at 30 °C. For rapamycin experiments, cultures were incubated for
5 days in the presence of the drug [13]. An aliquot of the cultures was
then placed in a ﬁnal concentration of 0.1% of the vital dye trypan blue
for 5 min. Viability was determined by phase contrast light-microscopy
observation by scoring the proportion of yeast cells that have taken up
and those that excluded the vital dye. The data from the viability exper-
iments are presented as the mean ± standard deviation (S.D.) of tripli-
cate experiments that were repeated a minimum of three independent
times. Statistical signiﬁcance of the data was determined by using a Stu-
dent t test. All results shown are signiﬁcant with p b 0.001.
2.3. Phenotypic analysis of cdc10Δmutants
The size of individual cells was determined using galactose growing
cultures of yeast transformants. The average size/area of yeast cells
was estimated based on cell-by-cell analysis using a Zeiss Axiovert
200 microscope connected to a camera (Q Imaging Retiga Ex). Phase-
contrast images (400×) were stored using Northern Eclipse software.
Cell area was determined using photoshop CS6 extended by individual-
ly encircling/selecting each cell, buds were not included. Daughter cells
were excluded if they measured less than 50% of the mother cell [27].
Pixel dimension was calibrated using an image of a micrometer scale
(hemacytometer) [28]. At least 100 cells of each culture were analyzed
and averages of the obtained cell areas were calculated.
3. Results and discussion
Here we report on the characterization of a Bax suppressor, Bh17,
encoding human septin7, which was originally identiﬁed in our previ-
ous screen of a human cardiac cDNA expression library [26]. Our ﬁrst
step was to conﬁrm that septin7 was a Bax suppressor. We therefore
isolated septin7 plasmid DNA from the yeast cells identiﬁed in the orig-
inal screen and the DNAwas retransformed alongwith the Bax express-
ing plasmid into wild type yeast BY4742. Freshly saturated cultures of
yeast cells transformed with the Bax expressing plasmid alone (with
empty vector) or with the septin7 expressing cells were serially diluted
and aliquots were spotted onto nutrient agar media with glucose or
with inducingmedia containing galactose. As a control we also included
cells harboring a galactose inducible human 14-3-3 cDNA that is a
previously characterized Bax suppressor [13]. All three strains show
the same growth on glucose media (Fig. 1). In contrast, growth of cells
expressing Bax alone was reduced when grown on galactose inducing
Fig. 1.Clone Bh17 is a Bax suppressor. Bh clone 17was previously cloned as a cDNA sequence that could prevent the lethal effects of Bax that is heterologously expressed in yeast cells. DNA
was obtained from the original clone and sequence analysis identiﬁed Bh17 as corresponding to human septin7. The septin7 cDNA was re-introduced into naïve BY4742 yeast cells with
and without Bax. The plasmid expressing the previously characterized Bax suppressor 14-3-3 was used as a positive control. Cultures of the different yeast transformants were serially
diluted with sterile water and aliquots were spotted onto glucose or galactose media. The plates were incubated for 5 days at 30 °C and photographs of the resultant plates are shown.
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crease the effects of Bax and these cells show more growth (Fig. 1).
These results conﬁrm that human septin7 is capable of suppressing
the negative effects of heterologously expressed Bax in yeast.
3.1. Identiﬁcation of a novel septin7 variant as a Bax suppressor
Sequence analysis of Bh17 revealed a 1.552 kb cDNA with an open
reading frame (ORF) encoding a predicted 407 amino acid sequence
that contains a 275 residue cdc–septin domain. Septins were ﬁrst iden-
tiﬁed genetically in yeast as cell division cycle (cdc) mutants cdc3, 10,
11 and 12 [29]. Comparison with the proteins in the GenBank database
revealed that the septin7Bh17 clonewas identical over a large part of its
sequencewith human septin7. In effect, alignment of the two sequences
reveals that the C-terminal 381 amino acids of the 407 residues within
Bh17 are identical to the C-terminal 381 residues of the 437 residues
of human septin variants (v) 1 and 2 (respective GenBank accession
nos. NM_001788 and NM_001011553) (Fig. 2A). The sequence of the
N-terminal 26 amino acids of Bh17 is unique since it was not found in
the GenBank databases. This suggests that Bh17 likely represents a
splice variant of the human septin7 gene.We called Bh17 septin7 v4 be-
cause a third septin7 variant, called v3, is already described in the
GenBank database (accession no. NM_001242956). This v3 variant is
virtually identical to v1 with the exception of a 36 residue deletion
near the N-terminal of the protein. The amino acids that are absent in
septin7 v3 are underlined in the sequence of v1 that is shown to be
aligned with v4 (Fig. 2A).
The available sequences of the septin7 variants including our Bh17
Bax suppressor suggest the human septin7 gene is alternatively spliced
to produce at least 3 different septin7 transcripts and proteins. In order
to conﬁrm this possibility we determined the exon/intron structure of
the human septin7 gene. This was accomplished by comparing the
septin cDNA sequences with the sequence of the human genome.
Using the sequence of a human septin7 v1 cDNA as a probe, 13 unique
regions of identity were identiﬁed in the human genome (Fig. 2B). The
identiﬁed regions were found on a roughly 100 kb genomic fragment
of chromosome 7 (base 35830000 to 35940000; NCBI Reference
Sequence NT_007819.17). These 13 genomic regions ranged in size
from 52 to 1054 bp (Table 1). The sequences were ﬂanked by appropri-
ate splice acceptor and splice donor sites indicating that they likely
represent exons (Table 1). All 13 exonic sequences spliced together
accounted for the entire sequence of the septin7 v1 cDNA. A schematic
representation of the exon–intron structure of the human septin7 is
shown in Fig. 2B. The absence of exon 2 in septin7 v3 accounts for the
absence of a 30 amino acid sequence in its N-terminus when compared
with variant 1. Given that the majority of the cdc/septin conserved
domain is encoded by exons 3–10, the N-terminally truncated v3 still
contains most of the conserved domain (Fig. 2B). On the other hand,
septin7 v4 contains an extra 14th exon, located between exons 2 and
3 (Fig. 2B). We have called this exon as 2A since it is new and unique
to v4. Exon 2A is 94 bp long and is ﬂanked by appropriate splice accep-
tor and donor sites indicating that it has the characteristics of an exon(Table 1). The presence of exon 2A alters the predicted amino acid
sequence of the N-terminus of septin7 v4. Instead of using the transla-
tional initiation codon present in exon 1 as is observed for variants 1–
3, the presence of exon 2A alters the translational frame and instead,
v4 uses a new start codon in exon 2A (Fig. 2B). This allows to produce
a cdc/septin domain containing septin7 protein with an N-terminus
that differs in size and amino acid composition from variants 1–3
(Fig. 2A). This new 26 residue N-terminal sequence is not present in
GenBank but it does show similarities to a number of different proteins
including 76% identity with a region of human brain myo41 protein
(residues 50 to 74; GenBank accession no. AAG43158.1). Other less
well characterized human septin7 variants exist including one of the
originally cloned human orthologs of yeast CDC10 (GenBank accession
no. S72008) [30]. This cDNA encodes a 418 residueN-terminally truncat-
ed formof septin7 that is lacking the ﬁrst 17 residues of variant 1. A tran-
script lacking exon 1 could account for this septin7 protein.
Alternative splicing is a commonly usedmechanism to generate pro-
tein structural and/or functional diversity from a single gene [31]. Alter-
native splicing is very commonly observed for all members of the
mammalian septin super family [32,33]. There are so many septin vari-
ants that the biological signiﬁcance of all this variation in protein coding
aswell as 5′ and 3′ Untranslated Transcribed Regions (UTRs) is not well
understood and is still being investigated [34]. For example human
septin4 is now reported to have a total of six distinct splice variants
(http://www.uniprot.org/uniprot/O43236). There is a great deal of struc-
tural and functional diversity in these variants. For example, human
septin4 isoform 2 is a well investigated pro-apoptotic variant that is bet-
ter known as ARTS (apoptosis related protein in TGF-β signaling path-
way) [35]. ARTS is a mitochondrial protein that induces apoptosis by
serving to block the anti-apoptotic function of the caspase inhibitors
IAPs (Inhibitors of Apoptosis). Although other splice variants of septin
4, namely isoform 1, appear to also have a pro-apoptotic function, the
role of all variants has not been investigated [36]. Alternative splicing
to produce functionally divergent proteins is of course not restricted to
the septin superfamily, it also appears to be a common occurrence for
genes involved in regulating apoptosis [37]. Thus it is not surprising
that the anti-apoptotic variant of human septin7 is a novel alternatively
spliced transcript and is in fact reminiscent of the fact that many of the
anti-apoptotic sequences that we have uncovered also represent novel
variants of otherwise commonly described proteins [26,38–40].
3.2. Yeast overexpressing human septin7 is resistant to copper-mediated
cell death
Septins can heterologomerize to form functional barriers that can
serve to sequester cellular components [41]. Thus it remains possible
that overexpression of human septin7 serves to prevent Bax mediated
cell death by sequestering the pro-apoptotic protein. To determine
whether septin7 is a general anti-apoptotic sequence, we examined
if it can protect cells in the face of another stress, other than Bax
overexpression. This is of importance because Bax induces multiple
forms of PCD in yeast [42]. The heterogeneous nature of the PCDs
AB
Fig. 2. Analyses of the sequences of the septin7 splice variants and characterization of the genomic organization of the human septin7 gene. A, the amino acid sequence of the 437 residue
commonly observed septin7 splice variant 1 (v1) is shown to be aligned to the deduced amino acid sequence of the splice variant 4 of septin7 identiﬁed here as the Bax suppressor Bh17.
The sequences of v1 and v4 differ only in the small region at their N-terminus. The underlined amino acid sequence in septin7 v1 represents the region that is missing in the otherwise
identical septin7 v3 protein. The numbers on the right correspond to the amino number in the sequence. A colon (:) is used to depict identical residueswhile a period (.) depicts conserved
residues. B, organization of the human septin7 gene. In order to determine the exon/intron organization of the human septin7 gene, the nucleotide sequences of all the available septin7
splice variants including variants 1–3 in GenBank (accession nos. NM_001788, NM_001011553 and NM_001242956) and the novel septin7 v4 (GenBank acc # KF305319) identiﬁed here
were compared to the available human genomic DNA sequence. The analysis revealed that the septin7 gene contains 14 different exonswhich are depicted as numbered boxes on the top
of the schema. The sizes of the exons as well as the conserved 5′ and 3′ ﬂanking splice sequences are shown in Table 1. The corresponding intronic sequences are shown as lines. The di-
agram is shown to scale. The sizes of the introns between the different exons are for exon 1 to exon 2: 31,527 bp; for exon 2 to exon 2A: 5661 bp; exon 2A to exon 3: 24,894 bp; exon 3 to
exon4: 9007 bp; exon4 to exon 5: 874 bp; exon5 to exon 6: 6047 bp; exon 6 to exon 7: 2543 bp; exon 7 to exon8: 1314 bp; exon8 to exon 9: 1840 bp; exon 9 to exon 10: 4789 bp; exon
10 to exon 11: 7450 bp; exon11 to exon12: 4592 bp; and exon12 to exon13: 1038 bp. The exonsmaking up the different cDNAs are shownbelow the genomic organization. Septin7 v4 is
the only variant that contains all the 14 different exons including the exon 2A identiﬁed in this study.
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cult since these sequences may induce resistance to only one type of
PCD. Here we treated our transformants with copper, a well known
apoptotic inducing agent [43]. One advantage to using such chemicals
is the ability control the level of stress. This allows one to exposed
cells to ﬁxed levels of stress. This is critical since the type of response
to any given type of stress is dependent on its intensity. In effect, the
response can range from the induction of pro-survival processes likeautophagy to necrosis [16]. We have previously shown that 1.8 to
2.2 mM copper sulfate was sufﬁcient to induce PCD that could be
prevented by overexpressed Bax suppressors including 14-3-3 (Eid
et al., submitted for publication). Freshly saturated cultures of yeast
transformants were diluted and grown in galactose inducing media for
4 h, serially diluted and spotted onto nutrient medium agar containing
glucose or the galactose inducingmedia. Yeast cells harboring the septin7
or 14-3-3 expressing plasmids are more resistant to the inhibitory effects
Table 1
Sequences of the intron–exon junctions of the alternatively spliced human septin7 gene.
Exon Exon size (bp) Splice acceptor site Splice donor site
(intron–EXON) (EXON–intron)
1 N254 5‵ end AGCACCATGG-gtgagtctca
2 103 cttttgtcag-CAACAGAAGA ATGGTAGTGG-gtaagatatg
2A 94 ttttttgtag-AGGTGATGTT AGGATTACAG-gtgtgagcca
3 107 tttcttttag-GTGAATCTGG GACTGTACAG-gtatggatat
4 101 actcttacag-GTGGAACAAT ATAGTAATTG-gtaagaaggg
5 135 cgttctatag-CTGGCAGCCT CAGGACATGG-gtcagtacct
6 118 tgtatttcag-ACTTAAACCA TAAAAAACAG-gtgagcagga
7 93 tccattttag-ATAATGAAAG AAAGATAAAG-gtaggttcat
8 97 tgttttatag-GACCGTTTAC GTTGCTGAAG-gtaagatttt
9 52 tttcttacag-TTGAAAATGG TGTTGATAAG-gtaagtgcaa
10 130 tttatgacag-AACACACATG GACTAAGTAA-gtatatattt
11 136 ttcgtgacag-GAGCCCTCTG TGAAGCTGAG-gtaatcagtc
12 140 tatgatttag-CTCCAGCGGC ACTCTTCAAG-gtaactaata
13 1054 tatcctttag-AACCTTGGAA TGTGATGTAA-poly A
The intron/exon boundaries were determined by comparing the sequences of the three
existing human septin7 cDNA variants (v1–3) described in the GenBank database
(accession nos. NM_001788, NM_001011553 and NM_001242956) as well the septin7
v4 described here (GenBank acc # KF305319) with the corresponding genomic DNA se-
quence found on chromosome 7 (NCBI Reference Sequence NT_007819.17). Introns are
shown in lower case and exons in upper case letters.
Fig. 3.Human septin7 v4 confers resistance to copper mediated cell death in yeast. A, cul-
tures of the yeast transformants harboring the control empty vector (Vector) or septin7 or
14-3-3 expressing plasmids were serially diluted and aliquots were spotted onto nutrient
agar plates containing glucose (Control) or galactosewith 2.0 mM copper sulfate (CuSO4).
Photographs of the plates were taken after 4 days incubation at 30 °C. B, cultures of the
different yeast transformants harboring the indicated plasmids were treated for 18 h
without (−, in black) or with (+, in white) 1.4 mM CuSO4. Samples were then taken,
treatedwith the vital dye trypan blue and percentage of live cells (% trypan blue negative)
was determined by phase contrast microscopy. The presented data are the mean ± stan-
dard deviation (S.D.) of triplicate experiments that were repeated for a minimum of three
independent times. * indicates that the value obtained is signiﬁcantly different than con-
trol vector cells using Student t test (p N 0.001).
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(Fig. 3A). The spot assay used heremeasures growthwhich is the product
of both the rate of cell division and cell death. To monitor cell death, we
therefore used a vital dye in order to directly determine viability after
treatmentwith copper. Freshly saturated cultures of yeast cells harboring
control or the septin7 or 14-3-3 expressing plasmids were grown for 4 h
in galactosemedia. These cellswere then challengedwith 1.4 mMcopper
sulfate and viability was determined after 18 h of further growth. In the
absence of added copper, viability for all strains was greater at 97%
(Fig. 3B). In contrast, the viability of control cells was decreased to
29.7 ± 1.9% when grown in the presence of copper (Fig. 3B). In contrast
the viability of cells harboring the 14-3-3 or septin7 expressing plasmids
was increased to a respective 79.0 ± 7% and 75.1 ± 2% (Fig. 3B). These
results indicate that human septin7 can prevent stress mediated
programmed cell death and can be given the classical label of being an
anti-apoptotic sequence [2].
A large number of stresses are known to induce PCDs. In order to
begin examining the range of stresses that can be prevented by septin7,
we examined the effects of rapamycin. Although rapamycin is a well
known inducer of autophagy, prolonged exposure leads to PCD. We
have previously shown that overexpression of human 14-3-3 is sufﬁ-
cient to prevent the effects of the PCD induced by rapamycin [13]. Seri-
ally diluted cultures of yeast transformants harboring human septin7 or
14-3-3 aswell as cells harboring empty vector were spotted on nutrient
agar media with and without rapamycin (Fig. 4). Because rapamycin
ﬁrst induces cell cycle arrest as it induces autophagy, it remains that
septin7 may simply promote growth or prevent cell cycle arrest. We
thus treated liquid cultures with rapamycin and directly examined via-
bility using trypan blue. Cultures of different transformants were treat-
ed with rapamycin for 5 days and viability determined. As previously
described, the viability of control cells was reduced with a value of
45 ± 4.2% in this study. Similarly as we previously described [13], we
observe here that the viability of 14-3-3 expressing cells remained
high with 88.1 ± 3.8% of cells still alive [13]. Septin7 also prevented
the lethal effects of rapamycin as 84 ± 5.2% of cells remained viable
after 5 days of treatment. Thus septin7 can prevent PCD induced by
rapamycin.
3.3. Human septin7 in a caspase deﬁcient (MCA1Δ) mutant
The mitochondria are the nexus of stress mediated apoptotic-like
PCD in yeast as it is inmammalian cells [44,45]. Yeast also shows a num-
ber of other similarities to mammalian cells in the processes that it usesto induce stress mediated PCD [3,5,16,21,46]. This includes the stress
mediated activation of key pro-apoptotic proteins such as caspase/
metacaspase and BH3 containing proteins [47]. The caspase protein
called YCA1/MCA1 (yeast caspase1/metacaspase1) is an important
gene that is activated and induces apoptotic-like PCD in response to a
variety of stresses [48]. As a ﬁrst step towards understanding how
septin7 is acting in the multitude of different PCD pathways, the anti-
apoptotic effects of septin7 were examined in a mutant strain lacking
MCA1Δ. Freshly saturated cultures of wild type andMCA1Δ cells harbor-
ing the empty vector or the septin7 or 14-3-3 overexpressing plasmids
were serially diluted and spotted onto nutrient agar plates with glucose
alone or with galactose and 2 mM copper sulfate (Fig. 5). Copper
inhibited the growth of both strains equally well and 14-3-3 as well as
septin7 protected both strains equally well (Fig. 5). These results indi-
cate that copper does not appear to require a functional MCA1 gene to
induce an apoptotic-like PCD. It should be noted that stress mediated
activation of PCD rarely is dependent on a single gene. In effect, there
is a great deal of cross-talk between the different PCD pathways such
that the knock-down of one pathway often leads to activation of alter-
native cell death pathways [2,49]. For example, it is well known that
in the absence of Bax, certain pro-apoptotic stimuli will still lead to
PCD using alternative autophagic or necroptotic like processes [50].
Fig. 4.Human septin7 v4 confers resistance to rapamycin in yeast. A, serially diluted aliquots of cultures of the yeast transformants harboring the control empty vector (Vector), human14-
3-3 or human septin7 expressing plasmids were spotted onto nutrient agar plates containing glucose (Control) or rafﬁnose and galactose with 100 mM rapamycin. Photographs of the
plates were taken after 4 days incubation at 30 °C.
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not appear to be themechanism bywhich septin7 prevents PCD. Deter-
mining the exactmechanismbywhich apoptotic inhibitors prevent PCD
can be problematic. There are simplistic cases such as genes encoding
proteins that remove pro-apoptotic second messengers such as ROS or
ceramide [2]. On the other hand there are proteins such as Bcl-2
which also appear to be functionally simplistic as they are known to
prevent PCD by sequestering pro-apoptotic Bax [51]. Nevertheless alter-
native anti-apoptotic mechanisms are suggested for Bcl-2 since it can
prevent PCD in the absence of Bax. Given the importance of septin to
the cytoskeleton and of actin in the regulation of PCD, the mechanism
by which septins serve to inhibit PCD is likely due to its interaction
with the cytoskeleton [52,53]. The ability to use yeast as amodel should
facilitate uncovering the importance of actin in the survival functions of
septin7 [54].3.4. The yeast septin7 ortholog CDC10 is also a pro-survival sequence
Septin7 belongs to the large septin super family of conserved Mg2+
binding GTPases that polymerize into heteromeric ﬁlaments to form
bundles or ring structures in vitro and in vivo and are involved in
diverse cellular functions [32]. Septins were ﬁrst discovered in neck
ﬁlaments of budding yeast [55] and subsequently found ubiquitously
present amongst metazoans [56]. The human genome encodes for 14
different septin genes and due to extensive alternative splicing, far
more septin proteins. All septins consist of a conserved septin/cdc
domain that includes a polybasic region and a GTP-binding domain of
the P-loop superfamily of GTPases [33 2682]. Their N- and C-terminal
regions vary in length and amino acid composition, and contain
proline-rich and coiled-coil domains. Septins are subdivided into four
sub-groups or families based on their structure [32,33]. The SEPT2 fam-
ily contains 4 members (septin 1, 2, 4 and 5), SEPT3 has threemembers
(septin 3, 9 and 12), SEPT6 has ﬁvemembers (septin 6, 8, 10, 11 and 14)
while septin7 is unique as the lonemember of the SEPT7 subfamily. The
large diversity of different septin proteins belies their importance in a
number of different cellular processes including bud formation, cytoki-
nesis, growth and viability as well as processes such as dendrite mor-
phogenesis and meiosis in mouse oocytes [57,58].Fig. 5. Analysis of the effects of septin7 in themetacaspase deﬁcientMCA1Δ yeast mutant. Wild
septin7or 14-3-3 expressingplasmidswere grown in liquidmedia, serially diluted and aliquots o
2 mM copper sulfate (+CuSO4). Photographs of the plates after incubation at 30 °C are shownThere are seven different septins in yeast. Four of these were ﬁrst
identiﬁed genetically as cell division cycle (cdc) mutants cdc 3, 10, 11
and 12 [56]. In addition to the four CDC genes, yeast is known to contain
a total of seven septin encoding genes including SHS1 and the sporula-
tion speciﬁc SPR3 and SPR28 [32,33]. In yeast, the septins are well
known as having several structural roles including being a component
of the septin ring that is required for cytokinesis. Their ability to interact
with phosphatidylinositol-4,5-bisphosphate and the observation that
protein abundance increases under DNA damage stress suggest more
complex functions [34,59,60]. Of interest is the fact that human septin7
is also known as Cdc10p [30,33]. Direct comparison of the amino acid
sequence of Cdc10 with the human septin7 sequence (GenBank:
DQ232879) was carried out using the Blast alignment tool (http://
blast.ncbi.nlm.nih.gov/) and shows that septin7 shows the most and
very similar sequence similarity to the four Cdc (3p, 10p, 11p and
12p) yeast septins. An alignment of the sequence of the human septin7
with that of Cdc10p shows that the shared 42% is spread throughout the
yeast sequence (Fig. 6). All four variants of human septin7, including v4
(shown in Fig. 6) has a longer C-tail than Ccd10p. This region consists of
α-helix and coiled-coil structures of ill deﬁned function [33]. To investi-
gate possible anti-apoptotic function of yeast septins we examined
yeast cells overexpressing CDC10. A spot assay was carried using yeast
strains harboring control empty vector, human 14-3-3 or the yeast
CDC10 septin. All strains grew the same on glucose media. In contrast,
copper inhibited the growth of control cells while cells overexpressing
CDC10 show the same resistance to copper as do cells harboring the
human 14-3-3 cDNA (Fig. 7A) and human septin7 (Fig. 3A). Finally,
we used to spot assay to examine if the yeast CDC10 gene can also pre-
vent copper mediated cell death. We treated cultures of both control
and CDC10 expressing cells with 1.4 mM copper for 18 and viability
was determined using trypan blue. The viability of control cells was
reduced to 24.7 ± 5.7% compared to CDC10 expressing cells where via-
bility was signiﬁcantly higher at 71.2 ± 3.3%. These results suggests
that anti-apoptosis is a common evolutionarily conserved function of
septin7.
In order to further characterize the potential of the Ccd10p to func-
tion as an anti-apoptotic sequence we co-expressed CDC10 with Bax.
Yeast cells harboring the Bax expressing plasmid with the empty vector
orwith the14-3-3 or theCDC10 expressing vectors show similar growthtype BY4742 (WT) or isogenic metacaspase (MCA1Δ) strains harboring the empty vector,
f the different dilutionswere spottedonto nutrient agarmediawithout (Control) andwith
.
Fig. 6. Comparison of the amino acid sequences of human septin7 v4with the yeast Cdc10p septin. The amino acid sequence of human septin7 v4 (GenBank acc. # KF305319)was aligned
with the amino acid sequence of Cdc10p from S. cerevisiae (GenBankacc. #NP_009928.1). The conserved septin/cdc domain present in the yeast Cdc10p is shownunderlined. The numbers
on the right correspond to the amino number in the sequences. A semi-colon (:) is used to depict identical residues while a (.) depicts conserved residues.
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contrast, Bax expression signiﬁcantly reduces yeast growth when
the cells are grown on the galactose inducing nutrient agar media
(Fig. 7B). The co-expression of 14-3-3 or CDC10 reverses the effects of
Bax and allows for signiﬁcant more growth of the cells (Fig. 7B). Taken
together the results presented in Figs. 1, 3 and 7 suggest that anti-
apoptosis is a common evolutionarily conserved function of septin7.
This is in contrast to other studies with septin7, which have demon-
strated that it can function as a tumor suppressor that can induce
apoptosis in cultured glioma cells [61,62]. As mentioned above these
results may have to do with the functional differences of the different
septin7 variants studied. Nevertheless such apparently conﬂicting func-
tions have been observed with other genes. For example, TSC22 gene 4
is pro-apoptotic in melanocytes but it has been shown to be anti-
apoptotic when overexpressed in mouse kidney cells or heterologously
expressed in yeast [39,63,64].Fig. 7. The yeast CDC10 reverses the effects of copper and Bax. Cultures of different yeast transfo
were spotted onto different nutrient agar media and allowed to grow. A, cells harboring empty
quence were spotted onto nutrient agar media containing glucose (Control) or galactose and c
nationwith an empty vector or the plasmids expressing the yeast CDC10 septin gene or the hum3.5. Human septin7 in a Cdc10Δ mutant
In addition to promoting increased stress resistance when
overexpressed, anti-apoptotic genes are often characterized by the in-
creased stress sensitivity that occurs when their genes are removed by
knock-out or if their basal expression is otherwise decreased say by
siRNA [2]. To examine this possibility for septin we made use of a yeast
mutant that is lacking Cdc10Δ. These cells are reported to showvery little
differences in terms of growth with wild type cells but they have
been reported to show increased sensitivity to the toxic effects of numer-
ous chemicals [65] (http://www.yeastgenome.org/cgi-bin/locus.fpl?
locus=cdc10). The Cdc10Δ mutant cells were thus transformed with
empty vector or with vectors expressing yeast CDC10, human septin7
or human 14-3-3. Freshly saturated cultures were serially diluted and al-
iquots were spotted onto nutrient agar plates with and without copper
(Fig. 8). The Cdc10Δmutants were sensitive to the effects of copper andrmants harboring the indicated plasmidswere serially diluted and aliquots of the dilutions
vector or the plasmids expressing the yeast CDC10 septin gene or the human 14-3-3 se-
opper sulfate (+2.0 mM CuSO4). B, cells harboring the Bax expressing plasmid in combi-
an 14-3-3 sequencewas spotted onto nutrient agarmedia containing glucose or galactose.
Fig. 8. Analysis of human septin7 and CDC10 sequences in a Cdc10Δmutant. A yeast mutant lacking the endogenous CDC10 gene was transformedwith control empty vector (Vector) or
with plasmids expressing the human septin7 v4, the yeast CDC10 or the human 14-3-3 sequence. Cultures of the transformants were serially diluted and aliquots were spotted onto nu-
trient agar media containing glucose (Control) of galactose and copper sulfate (+2.0 mM CuSO4). The plates are shown photographed after 4 days of incubation at 30 °C.
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effect. Surprisingly the expression of human 14-3-3 also reversed the
effects of copper on the Cdc10Δmutant. Further the sensitivity to copper
in the Cdc10Δmutant was observed to actually be decreased compared
to what is observed in the wild type cells (Fig. 8). We cannot explain
possible reasons for this change. Nevertheless, this indicates that
Cdc10Δmutant is not supersensitive to the stress of copper and instead
copper was just inducing a normal apoptotic-like PCD in these cells.
Thus the yeast CDC10 is not a classical anti-apoptotic gene. This is likely
due to the fact that the other septin containing CDC genes such as CDC
2, 11 or 12 is likely to be able to at least partially compensate for the
loss of CDC10.
The structural similarity between yeast and human genes allows the
functional expression of many human genes in yeast [21–23]. We
sought to determine if human septin7 could complement speciﬁc
phenotypes associated with the loss of CDC10. One phenotype associat-
ed with Cdc10Δ mutants is an increase in cell size {Jorgensen, 2002
#2670]. This difference is readily apparent by simple microscopical
examination of growing cells. The functional signiﬁcance of this pheno-
type is not known but it is thought to be associated to a loss of structural
integrity provided by Cdc10p. In spite of this phenotype Cdc10Δ
mutants are reported to have no discernable differences in their rate
of growth compared to wild type cells [65]. In galactose growing cells,
we observed that Cdc10Δmutants are signiﬁcantly larger with an aver-
age size of 22.9 μm2 ± 0.5 compared to the average size of 15.6 μm2 ±
0.4 for wild type cells. This represents close to a 50% increase in cell size
for the Cdc10Δmutant. A systematic analysis of the sizes of all gene de-
letion yeast strains showed that Cdc10Δmutants represent the largest
cell examinedwith a N70% increase in size [66]. Our results are basically
in agreement with these published results in spite of methodological
differences such as the fact that we use minimal synthetic YNB
media for growing our cells. The average size of Cdc10Δ mutant
cells overexpressing human septin7 was 20.1 μm2 ± 0.6. As a con-
trol we also determined that the average cell size of Cdc10Δmutant
cells overexpressing CDC10was observed to be 22.3 μm2 ± 0.6. This
lack of complementation by the homologous CDC10 suggests that
overexpression of septin7 or CDC10 leads to a similar phenotype as
the loss of CDC10. Strategies involving the expression of septin7
from centromeric plasmids or gene “knock-in” experiments will be
required to carry out a ﬁne tuned phenotypic analysis of septin7 in
yeast. Nevertheless, these results suggest that the anti-apoptotic
function of septin7/CDC10 can be dissociated from its role in
maintaining cell size.
The altered expression of many different septins is commonly ob-
served inmany tumors [32–34]. This deregulation is mademore critical
by the fact that many septins are known to be regulators of growth and
cell death with many acting as tumor suppressors or oncogenes. An
association between the resistance to chemotherapeutic drugs, most
noticeably microtubule destabilizing agents such as taxol, and alter-
ations in the level of several different septins has been widely reported
[60,67–69]. Surprisingly, some such as septin9 are up-regulated whileothers such as septin10 are downregulated. This differential regulation
also belies functional differences. Thus the overexpression of septin10
suggests that it functions to induce apoptosis while the overexpression
of septin9 suggests that this septin serves to protect cells from apoptosis
[60,67,68]. Recent studies suggest that the association with mitochon-
dria may be part of the mechanism by which both pro- and anti-
apoptotic septins may work to regulate cell viability [35,70]. Very few
studies have examined a potential role for yeast septins or for septin7
in regulating cell survival. Two studies from the same group demon-
strate that septin7 can inhibit tumor cell growth when overexpressed
and provide evidence that septin7 may in fact be a tumor suppressor
[61,62]. These studies were carried out with the poorly characterized
418 amino acid septin7 variant that was one of the originally identiﬁed
orthologs of the yeast CDC10 encoding septin [30]. The ability to func-
tionally characterize heterologously expressed individual septin7 splice
variants in yeast should facilitate our understanding of their different
roles in the regulation of cell death/survival.Acknowledgements
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